All posts by medical

HFEA publishes 2018 trends in fertility treatment – BioNews

6 July 2020

The Human Fertility and Embryology Authority (HFEA)has published its latest analysis on trends in fertility treatment, based on data from across the UK in 2018.

Headline findings include an increase in IVFsuccess rates, a surge in eggand embryofreezing, and a decrease in NHSfunding for fertility treatments.

Sally Cheshire, chair of the HFEA, said: 'While fertility treatment is never a guarantee for a baby, we are pleased to see that birth rates have increased over the years and the average birth rate is now steady at 23 percent. Whilst this leaves many couples without their longed-for family after treatment, these small year-on-year increases are important for the sector to build on.'

In 2018 about 54,000 patients underwent 68,724 fresh and frozen IVFcycles and 5,651 donor insemination cycles at HFEA licensed fertility clinics across the UK. IVF birth rates increased for all patient groups under the age of 43 over time. Patients below the age of 35 had a birth rate of 31 percent per transferred embryo (23 percent for all patients), an increase from only nine percent in 1991, when HFEA was established.

Age remains a key factor for IVF success, with a birth rate below five percent for women over 43 who use their own eggs.

Multiple pregnancy, one of the main risk factors of IVF, has for the first time fallen to eight percent, as it has become clear that implanting more than one embryo has no significant impact on the chance of live birth.

The report also states that the number of patients choosing embryo and egg storage cycles increased five-fold from 1400 in 2013 to 9000 in 2018. The number of women freezing unfertilisedeggs has also climbed from 569 in 2013 to 2000 in 2018. Frozen embryo transfers are now more successful than fresh ones, although only by a small margin.

Sarah Norcross from the Progress Educational Trust said: 'The women we have spoken to value motherhood and having a family is really important to them and so they are choosing to freeze their eggs as a back-up plan in case they need them in the future. Of course, they may not need them as they may find a partner and get pregnant the old-fashioned way. I think there is a greater awareness of egg freezing as a reproductive choice and also of the biological clock and so women are choosing to invest money in trying to improve their reproductive options'.

The level of NHS funding for fertility treatment varies across the UK: In Scotland, 60 percent of fertility treatments are funded by the NHS, but in England where funding is controlled locally by clinical commission groups (CCGs), this figure has fallen below 30 percent in some areas.

'What is hugely disappointing is the continued fall in NHS-funded cycles... Whilst the Nice [National Institute forHealthand Care Excellence] guidance states that all eligible couples should be entitled to three full cycles (including the use of frozen embryos)' said Professor Adam Balen, the Royal College of Obstetricians and Gynaecologists spokesperson on reproductive medicine. 'IVF is cost effective and has shown to be an economic benefit to society.'

Read more here:
HFEA publishes 2018 trends in fertility treatment - BioNews

Adelaide fertility software launches in the UK, Europe – InDaily

adelaide Monday July 06, 2020

An Adelaide-based company that uses artificial intelligence to increase the chance of pregnancy through IVF has launched its software application in the UK and Europe.

Life Whisperer, the fertility arm of AI healthcare company Presagen, commercialised its flagship product in Australia in late January and released it through a distributor into India, Sri Lanka and Bangladesh last month.

Approvals are also being sought to sell the software tool in Japan, Southeast Asia and the US, where it has conducted a number of clinical trials.

Last weeks launch into the UK and Europe is a major step in the three-and-a-half-year journey for the product, which was forced into a COVID-19 hiatus from March to May when many of the worlds fertility clinics closed their doors.

Get InDaily in your inbox. Daily. The best local news every workday at lunch time.

Thanks for signing up to the InDaily newsletter.

Presagen currently has 15 staff and small offices in San Francisco and London to drive the global expansion.

Founder and CEO Dr Michelle Perugini said the company had strong connections in the UK and Europe and a number of clinics were already trialling the product in the region.

She said getting clinics on board as commercial customers was the next stage.

Regulatory approval in the UK and Europe represents a significant opportunity for Life Whisperer to expand its global presence, and we are very much looking forward to working with clinics and patients across the region, supported from our London Offices, she said.

Its a secure web-based application that is completely scalable so we can set up new clinics within minutes anywhere in the world.

Life Whisperer co-founders Dr Jonathan Hall (left), Dr Michelle Perugini and Dr Don Perugini. Picture: Matt Loxton.

The Embryo Viability Application for IVF clinics uses artificial intelligence to analyse images of embryos to assist clinicians to identify which embryo will likely lead to a pregnancy.

By selecting the best embryo, Life Whisperer aims to shorten the time to pregnancy and improve outcomes for couples undergoing IVF treatment.

An international study recently published in the journal Human Reproduction involved blind evaluation of 1600 IVF embryos.

Life Whisperer was shown to perform 25 per cent better than traditional manual methods of embryo assessment by highly experienced embryologists.

The technology will be showcased on Tuesday night Australian time at the 36th Annual Meeting of the European Society of Human Reproduction and Embryology, which is being held online this year.

Internationally renowned fertility expert Matthew (Tex) VerMilyea from Ovation Fertility (USA) will present Life Whisperers latest advances in AI for IVF at the event where Presagen will also have a virtual exhibition booth .

Dr Perugini said Presagen was planning a significant capital raise this year to drive growth.

She said the company was looking forward to working with IVF clinics across the globe to offer Life Whisperer to patients at a low cost, meaning more couples could gain more certainty in embryo selection and achieve success sooner, with fewer IVF cycles.

Life Whisperer is poised to become the global gold standard embryo pre-screening tool in IVF, supporting the clinical decision about which embryo is most viable.

Dr Perugini and Presagen CTO Dr Jonathan Hall are both past winners of InDailys 40 Under 40 Awards, which recognises South Australias top business leaders aged under 40.

Nominations are still openfor this years 40 Under 40 Awards with judging to commence in August before the awards are held in October.

In times like these InDaily provides valuable, local independent journalism in South Australia. As a news organisation it offers an alternative to The Advertiser, a different voice and a closer look at what is happening in our city and state for free. Any contribution to help fund our work is appreciated. Please click below to donate to InDaily.

Powered by PressPatron

Original post:
Adelaide fertility software launches in the UK, Europe - InDaily

Immunity to the coronavirus is ‘fragile’ and ‘short lived,’ immunologist warns – CNBC

It is not a "safe bet" to rely on immunity to Covid-19 as a strategy for coping with the pandemic, one expert has warned, adding that herd immunity strategies were "probably never going to work."

Speaking to CNBC's "Squawk Box Europe" on Monday, Danny Altmann, professor of immunology at Imperial College London, said that in towns and cities where there had been coronavirus infections, only 10% to 15% of the population was likely to be immune.

"And immunity to this thing looks rather fragile it looks like some people might have antibodies for a few months and then it might wane, so it's not looking like a safe bet," he said. "It's a very deceitful virus and immunity to it is very confusing and rather short lived."

He also raised questions about the likely success of so-called herd immunity when a population is allowed some exposure to the virus in order to buildimmunity among the general population which has been cited by health officials in Sweden, which controversially avoided a lockdown.

Despite a global race to find a vaccine for the coronavirus, experts remain uncertain about whether the antibodies present in people who have had the virus actually provide immunity to reinfection.

Top White House health advisor Dr. Anthony Fauci speculated last month that if Covid-19 behaved like other coronaviruses, there "likely isn't going to be a long duration of immunity" from antibodies or a vaccine. Meanwhile, the WHO has stated that it remains unclear whether those who have already caught the virus once will be immune to getting it again.

Imperial College London's Altmann said on Monday that he was expecting a second wave of Covid-19, and that although governments were much better prepared for a resurgence in infections, the situation remained "very, very scary."

"Anybody who thinks that it has got more mild or gone away or that somehow the problem's going to solve itself is kidding themselves," he told CNBC. "It's still a very lethal virus, it still infects people very, very readily. And I think humanity isn't used to dealing with those realities."

He also emphasized that it was difficult to make predictions about if or when an effective vaccine for Covid-19 might be identified.

"The devil is in the detail, vaccines aren't that easy," Altmann said. "There's more than 100 in trial at the moment and many things can go wrong along the way. I place no bets at the moment myself."

David King, former chief scientific adviser to the U.K. government, warned in an interview with Sky News on Sunday that the U.K. would have an additional 27,000 deaths from Covid-19 if it stayed on its current trajectory. To date, 44,305 people have died from Covid-19 in the U.K., according to data compiled by Johns Hopkins University.

Altmann told CNBC that he agreed with this projection "to some extent," claiming that a lot of scientists, immunologists and vaccine experts still felt "very scared" about the pandemic.

He acknowledged that policymakers needed to find a balance between protecting public health and preventing socioeconomic disasters, but added: "We need to continue to be led by the science and the medicine and do the right thing. And doing the right thing means everything you can do to block transmission."

The new strain of coronavirus, first reported to the WHO in late December, has infected more than 11.4 million people and killed 534,825 globally to date, according to data compiled by Johns Hopkins University.

Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, warned last week that the pandemic was accelerating around the world as economies began to reopen.

View original post here:
Immunity to the coronavirus is 'fragile' and 'short lived,' immunologist warns - CNBC

Aichi Cancer Center and NEC Aimed at Advanced Cancer Immunotherapy – AiThority

Through the Fusion of AI and Experimental Immunology

Aichi Cancer Center(1) and NEC Corporation announced the launch of fundamental research aiming to realize the promise of advanced personalized cancer immunotherapy by improving the performance of NECs neoantigen prediction system and developing predictive biomarkers for patient stratification through the fusion of AI and experimental immunology.

This research aims to identify suitable neoantigen for vaccine use by using the neoantigen prediction system which NEC has been working on and the screening techniques using T cells for neoantigen from Aichi Cancer Center. In addition, this research aims to develop biomarkers for patient stratification using AI based on analytical data on a tumor immune microenvironment and clinical data.

The partners will realize the promise of advanced personalized cancer immunotherapy which boosts the immune system especially in combination with immune checkpoint inhibitors (ICIs).

Recommended AI News: Amazon Web Services (AWS) Launches New Space Technology Segment

Although the ICIs showed a certain degree of therapeutic success in cancer therapeutics, the therapeutic effect is limited to few cases. Previous studies have suggested that there is a significant correlation between tumor neoantigen load and the clinical efficacy of ICIs. Accordingly, the immunotherapy could improve the therapeutic efficacy if the brakes on the immune system are disabled, and at the same time, the immune responses to neoantigens are accelerated. The important things for realizing effective cancer immunotherapies are 1.) the selection of neoantigens that harness the immune system and 2.) the patient stratification in treatment planning for ICI therapy, cancer vaccine therapy, and their combination therapy.

The Division of Translational Oncoimmunology at the Aichi Cancer Center has been conducting translational research using patient samples in collaboration with the departments of Thoracic Surgery and Thoracic Oncology at the Aichi Cancer Center Hospital. Specifically, this division specializes in experimental immunology and focuses on analyzing the immune microenvironment and the tumor-specific immune responses of each patient.

NEC is actively working on applied research in the drug development field using AI and has developed a unique AI-based neoantigen prediction system. NEC was accepted into the Tumor neoantigEn SeLection Alliance (TESLA) consortium given the uniqueness of this system and became the first Japanese company to join TESLA, founded and managed by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute.

Recommended AI News: Fujitsu And NetApp Introduce Data Management Infrastructure For HPC

1. Performance improvement of the neoantigen prediction systemAichi Cancer Center and NEC will identify neoantigens recognized by T cells by using both the neoantigen prediction system and the immunological experimental approach. In the future, NEC will improve the performance of the neoantigen prediction system by using this high-quality data.

2. Development of biomarkers for patient stratificationAichi Cancer Center and NEC will comprehensively analyze the tumor immune microenvironment of each patient. This research aims to develop biomarkers for patient stratification using AI based on clinical information, genetic mutation, gene expression, and experimental data obtained from the experiments described above.

Aichi Cancer Center will aim to carry out clinical trials of cancer immunotherapy. The clinical trials of cancer immunotherapy will be conducted at Aichi Cancer Center Hospital, and additional research will be conducted at Aichi Cancer Center Research Institute. The hospital and research institute will work together as a comprehensive cancer center.

NEC has been conducting applied research in the drug development field using AI for about 20 years. Through this joint research, NEC will accelerate its AI-driven drug development business by improving the performance of neoantigen prediction systems and developing biomarkers for patient stratification.

(1) Aichi Cancer CenterDesignated by Japans Minister of Health, Labour and Welfare as a hub hospital for cancer genome medical care.(2) NEC becomes the first Japanese company to join the TESLA consortiums fight against cancerhttps://www.nec.com/en/press/201905/global_20190514_01.html

Recommended AI News: AiThority Interview With Pankaj Chowdhry, CEO And Founder At FortressIQ

Share and Enjoy !

Read more:
Aichi Cancer Center and NEC Aimed at Advanced Cancer Immunotherapy - AiThority

More calls for masks in the Hillsborough County Schools – Tampa Bay Times

TAMPA In advance of Tuesdays meeting of the Hillsborough County School Board, proponents of mandatory masks at school have continued to call for a stricter policy.

A letter to that effect went out over the weekend, signed by close to 200 people who identified themselves as physicians. We are printing the petition below.

So far, the district has said it is providing a limited number of reusable masks for children, but only encouraging their use.

PREVIOUS: Parents: Children should wear masks to school

Calls went out over Facebook for concerned citizens to gather outside the School Board building at 3:30 p.m. for a socially distanced, masked protest. Those interested were also asked to address the board during the public comment period. The initial announcement said the Hillsborough Classroom Teachers Association was behind this event. But union spokeswoman Stephanie Baxter-Jenkins said it was not a union-organized event, and a notice went out later clarifying that fact.

Either way, interest is high on the subject of masks.

Tuesdays board meeting begins at 4 p.m. at 901 E Kennedy Boulevard.

The letter:

Dear Superintendent Davis and Hillsborough County School Board:

As a concerned group of Pediatricians and Physicians serving children and teachers/staff in Hillsborough County, we urge you to mandate masks and face coverings in our public schools during this global pandemic of COVID-19.

The American Academy of Pediatrics recommendations in COVID-19 Planning Considerations: Guidance for School Re-entry (attached) indicate that masks and face coverings are high priority for elementary, middle, and high school students.

Exemptions to wearing masks for children with individualized education plans or with medical conditions that would prohibit safe and effective use of masks should be handled on a case-by-case basis. Though some of our youngest (pre-school and kindergarten) students may be initially unable to wear a mask the full school day, with time and proper modeling, many of these young students may be able to properly wear masks when social distancing is not possible.

At a population level, masks are undeniably useful at reducing cases of COVID-19 in our community. Mask usage is most effective when all persons wear them, and families that chose to not wear masks endanger others by risking asymptomatic or pre-symptomatic spread of the virus. Mandating masks in our schools can: 1) prevent spread of viral infection that will compromise the health of children, their families and school employees, 2) reduce outbreaks that will threaten school or classroom closure 3) prevent unnecessary time off work for parents, staff and teachers, and 4) save health care resources of our pediatric practices which will be tasked with testing and clearing students for return to school.

We appreciate the hard work of our educators and administrators in Hillsborough County. We value the guidance and commitment of our School Board to make schools safe, accessible, and academically robust. We hope that you will follow the recommendations of the American Academy of Pediatrics and make masks and face coverings required for students and faculty in our schools.

https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-planning-considerations-return-to-in-person-education-in-schools/

Sincerely,

1. Anne M. Lenz, MD (Pediatrician, Endocrinology)

2. Tiffany Hernandez, MD (General Pediatrician)

3. Kiersten Hartlage, MD (General Pediatrician)

4. Leigh J. Ruth, MD (Child and Adolescent Psychiatry)

5. Sapnalaxmi Amin, MD (Family Medicine)

6. Rachel Irby, MD (Internal Medicine, Infectious disease)

7. Alisa Pierce-Kee, MD (General Pediatrician)

8. Grace Dougan, MD (Pediatrician, Endocrinology)

9. Rebecca Pruitt, MD (General Pediatrician)

10. Karina A. Parilo, MD (Family Medicine)

11. Shikha Sharma, MD (Internal Medicine)

12. Crystal Jacovino, DO (Internal Medicine)

13. Elisa Thompson, MD, FAAFP (Family Medicine)

14. Lindsey Bowser, MD (Family Medicine)

15. Melinda Murphy, MD, FAAP (General Pediatrician)

16. Monique Sajjad, DO (Hematology-Oncology)

17. Eric Schilling, DO (Pulmonary Critical Care)

18. Paul Nanda, MD (Urgent Care Medicine)

19. Leslie Turner, MD (Pathology)

20. Edgard Janer, MD (Rheumatology)

21. Richard Wilde, MD, FAAP (General Pediatrician)

22. Preeti Kallu, MD (Internal Medicine)

23. Heather Simpson Khanna, MD (Adult and Adolescent Psychiatry)

24. Amanda Sergay, MD (Dermatology)

25. Lilly Chang, MD, DDS (Pediatric CranioMaxillofacial Surgery)

26. Eva Gupta, MD (Hematology-Oncology)

27. Parul Aneja, MD (Infectious Disease)

28. Anil Chopra, MD (Infectious Disease)

29. Kate Knupp, MD (Internal Medicine, Pediatrics)

30. Catherine Kubiak, MD (Allergy Immunology)

31. Maria del Pilar Cekan, MD (Family Medicine)

32. Alex Anton, MD (General Pediatrics)

33. Jacqueline Hartman, MD, FAAP (General Pediatrician)

34. Christina Paulson, MD (General Pediatrician)

35. Shara Young, MD (OB-Gyn)

36. Catherine Hough-Telford, MD (General Pediatrician)

37. Rachel Rapkin, MD, MPH (OG-Gyn)

38. Andrew Galligan, MD (Pediatric Hematology-Oncology)

39. Lisa Rush, MD (General Pediatrician)

40. Matt Minick, MD (General Pediatrician)

41. Francesca Sabia, MD, FAAP (General Pediatrician)

42. Eliana Piedrahita-Llano, MD (General Pediatrician)

43. Gwennaelle A. Wilson, MD, MPH, FAAP (General Pediatrician)

44. Mary Chrisochos, DO, FAAP (Pediatrician)

45. Jennifer White, MD (Psychiatry)

46. Bhumi Kumar, DO, FAAP (General Pediatrician)

47. Elizabeth Harris, MD (General Pediatrician)

48. Natasha Hughes, MD (General Pediatrician)

49. Nay Hoche, MD (OB-Gyn)

50. Madhurima Sanka, DO (Pediatrics, Allergy and Immunology)

51. Sheila Mak, DO (General Pediatrician)

52. Rachel Epstein, DO, FAAD, FACMS (Dermatology)

53. Celia Williams, DO (General Pediatrics)

54. Solimar Salud, MD (General Pediatrics)

55. Lauren Sequeira, MD (Family Medicine)

56. David Van, DO (Family Medicine)

57. Ria Ross, DO (Dermatology)

58. Jennifer Pesce, MD (General Pediatrician)

59. Tracey DeLucia, MD, PhD, FAAOS (Pediatric Orthopedic Surgery)

60. Danita Wongchantara, MD (Primary Care Medicine and Pediatrics)

61. Julie Dekle, MD (General Pediatrician)

62. Ashley McPhie, MD (General Pediatrician)

63. Sara Ansari, DO (General Pediatrician)

64. Anjali Nirmalani-Gandhy, MD (Child Psychiatry)

65. Ana Maria Oliva, MD (Ophthalmology)

66. Beena Wilkins, MD (General Pediatrician)

67. Rosmery Victoria, DO (Family Medicine)

68. Jennifer Sawka, MD (General Pediatrician)

69. Carolyn Robinson, MD, FAAP (Pediatrician, Pulmonology)

70. Theresa Dam Lohmiller, MD (Family Medicine)

71. Jean Del Valle, MD (Child Psychiatry)

72. Laura Cruse, MD (Rheumatology)

73. Denise Edward, MD (Internal Medicine- Pediatrics)

74. Tsu-Hui Lin, MD (Pediatrics, Endocrinology)

75. Kelly Grabbe, DO (Emergency Medicine)

76. Lisa Hayes, DO (General Pediatrician)

77. Maliena Longley, MD (Pediatrics, Allergy and Immunology)

78. Dolores Razman, MD (General Pediatrician)

79. Michelle Mendoza, MD (Emergency Medicine)

80. Julie Hallanger Johnson, MD (Endocrinology)

81. Lisa Champoux-Rhoden, MD (General Pediatrician)

82. Kimberly Hartney, MD (Psychiatry)

83. Marsha Ramsay, MD, FAAP (General Pediatrician)

84. Shahla Escobar, MD (Pediatric Anesthesiology)

Read this article:
More calls for masks in the Hillsborough County Schools - Tampa Bay Times

Taoiseach fears international travel will reignite spread of coronavirus – Belfast Telegraph

Taoiseach Micheal Martin says there are fears that international travel will cause a resurgence in coronavirus and reiterated advice that people should not travel overseas.

he Cabinet is meeting on Monday to discuss the restrictions, although agreen list of countries where it is safe to travel to and from without having to quarantine is not expected to be published until July 20.

Mr Martin said: The travel advisory for the last while had been strong that its not advisable to travel overseas. We have to put public health first. That is the overarching issue.

Today the Cabinet will meet and make a formal decision on travel. We had a Cabinet sub-committee on Covid on Friday. The public health advice is extremely cautious now in relation to opening up for travel.

Close

The Cabinet is meeting to discusss the restrictions (Julien Behal/PA)

PA

Asked about when the Government will publish a list of green countries where it will be safe for Irish people to travel, Mr Martin said the matter was under constant review because the situation is changing very rapidly.

He said the Government is drawing up the list of countries, but noted there are countries where there are high numbers of cases.

We have countries that would have made the safe list two weeks ago wouldnt make it today, so the overarching objective is to suppress the virus and keep it down. There is a fear international travel could reignite the virus, he told Corks 96FM.

Meanwhile, Professor Kingston Mills said asking people travelling into Ireland from abroad to self-isolate for 14 days is not working.

That restriction was supposed to be lifted on Thursday of this week, but it is now expected to be extended until July 20 and then reviewed every two weeks thereafter.

Prof Mills, professor of experimental immunology and head of the Centre for the Study of Immunology at Trinity Biomedical Sciences Institute in Dublin, said Ireland has done well in suppressing the spread of coronavirus but allowing unrestricted travel into the country would unravel this.

Were one of the countries with the lowest levels of the virus in Europe and were an island. We have a chance to do even better than we have done in terms of completely eliminating the virus and preventing any further surges of the virus, he told RTEs Morning Ireland.

The idea of non-mandatory self isolation is not really working as I understand there are a significant amount of people not self-isolating or they are not being followed up.

People are effectively ignoring the advice from Government not to travel because you only have to look at the number of flights going in and out of Dublin to see that.

Close

People arriving in Ireland are expected to self-quarantine for 14 days (Brian Lawless/PA)

PA

Prof Mills said there are some European countries that may be safe to travel in and out from but he noted there are cities in the US where there are high numbers of cases.

Theres flights coming into Ireland from places like Chicago where they have a significant number of cases. If you have unrestricted flights coming in and people are not self isolating when they get here, then you are asking for trouble in terms of the virus resurging.

One more person has died with Covid-19 in Ireland on Sunday.

There has now been a total of 1,741 related deaths in the country, the National Public Health Emergency Team said.

PA

Originally posted here:
Taoiseach fears international travel will reignite spread of coronavirus - Belfast Telegraph

Auto Injectors Market Revenue Growth Defined by Heightened Product Innovation – 3rd Watch News

An auto-injector is a small, pen shaped device, which contains a hypodermic needle used for delivering a fixed dose of drug to patients. The drug is delivered by inserting the syringe needle at the desired site of injection, and on a push of a button. The site of insertion usually depends upon the nature of the drug to be administered, however intramuscular route is the preferred route of administration. Most of these auto-injector devices are spring loaded, pre filled syringes, and are used during serious allergic reactions also known as anaphylaxis or anaphylactic shock, and also in the cases of rheumatoid arthritis, and multiple sclerosis among others. Auto-Injectors are easy to use, and intended for self-administration by patients or any other care taker or personnel at home.

Increasing prevalence and incidences of anaphylaxis and food allergies around the world is majorly responsible for the growth of the global auto-injectors market. According to American Academy of Allergy Asthma and Immunology (AAAAI) around 15 Mn people in U.S. suffered from food allergies in 2015, while 17 Mn people in Europe out of which 3.5 Mn children suffered from food allergies in 2015 according to European Academy of Allergy and Clinical Immunology (EAACI). World Health Organization (WHO) estimated around 200 250 Mn people in the world suffered from food allergies in 2015. The increasing prevalence of anaphylaxis is increasing demand for adrenaline, and epinephrine auto-injectors, in the global market. Furthermore, new formulations and new drug delivery systems, combined with innovation and developments in the biological drugs segments are expected to drive the growth of the global auto-injectors market during the forecast period of 2016-2024. Rising self-medication practices, growing demand for targeted drug delivery systems for treatments of chronic diseases, coupled with government reimbursements and marketing approvals for auto-injectors are some other factors that are fuelling the demand for auto-injectors in the global market. However, higher prices for injectors, lack of practices of self-injection in emerging countries, and presence of substitute products are certain factors that are restraining the growth of the global auto-injectors market.

To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/12580

The global market for auto-injectors is segmented on basis of product, application, distribution channels and geography:

Based on product type segmentation, the disposable auto-injectors dominated the global auto-injectors market in 2015 in terms of value, and it is expected to continue this dominance during the forecast period of 2016-2024. Factors such as rising patient awareness and inclination of patients towards self-administration, increasing demand for auto-injectors due to increasing prevalence of anaphylaxis, and other emergency conditions, combined with easy to use disposable auto-injectors, are some factors that are expected to drive the growth of disposable auto-injectors segment in the global auto-injectors market during the forecast period of 2016-2024. Based on applications, the anaphylaxis segment is expected to dominate the global auto-injectors market during the forecast period of 2016-2024.

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/12580

On the basis of regional presence, global auto-injectors market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to lead the global auto-injectors market in terms of revenue owing to the advanced healthcare infrastructure, advancements in medical devices technologies, higher demand for quality products, and availability of reimbursement policies. According to World Health Organization (WHO), an estimated 26 Mn people in U.S. suffered from allergies, and according to Healthline Networks, an estimated 400,000 people in the U.S., and 2.5 Mn people around the world suffered from multiple sclerosis in 2015 with over 400 new cases of multiple sclerosis identified each week in the U.S. Asia Pacific market is anticipated to grow at the fastest growth rate during the forecast period, owing to factors such as increasing anaphylaxis and food allergies in countries such as China, Japan, Singapore, Australia and India. According to Australian Society of Clinical Immunology and Allergy (ASCIA), Australia and New Zealand topped the list of countries with most prevalence of food allergies in 2015 followed by Japan, Singapore, and Thailand. Growing medical tourism and high growth of the medical devices industry in these countries, is expected to drive the growth of the global auto-injectors market during the forecast period of 2016-2024.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/12580

Some of the major players in global auto-injectors market are

The rest is here:
Auto Injectors Market Revenue Growth Defined by Heightened Product Innovation - 3rd Watch News

Global Leukapheresis Market is Expected to Reach at a CAGR of 9.60% from 2018 to 2025 – PharmiWeb.com

A new research report published by Fior Markets with the titleGlobal Leukapheresis Market by Type (Leukapheresis Devices, Leukapheresis Disposables), Application, End-Users, and Region and Global Forecast 2018-2025.

As per the report, theglobal leukapheresis marketis expected to grow from USD 19.29 Million in 2017 to USD 41.07 Million by 2025 at a CAGR of 9.60% during the forecast period from 2018-2025. Asia Pacific is expected to dominate the market during the forecast period. Ongoing regenerative medicine research in the region, rise in the number of clinical trials and the presence of leading pharma and biotech companies in the region are some of the major factors driving the growth of the market in region.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/375981/request-sample

Prominent players operating in the market are Asahi Kasei Medical Co., Ltd, Macopharma SA, Fresenius Se & Co. KGaA, Bioivt, Haemonetics Corporation, PPA Research Group, Inc., Hemacare Corporation, Key Biologics, LLC, Terumo BCT, ALLCells, LLC, Stemexpress, LLC, Stemcell Technologies, Inc., Caltag Medsystems Limited, Zenbio, Inc, Precision for Medicine, Inc and others. Major firms are incorporating various strategies to increase their market reach. For instance, in April 2018, Fresenius Kabi expanded its production site for medical devices in Dominican Republic (U.S). This plant manufactures and exports apheresis systems for plasma and platelet collection. This new production facility has enhanced its production capabilities to meet the demand for apheresis systems.

The type segment is classified into leukapheresis devices and leukapheresis disposables. The leukapheresis disposables segment accounted for the largest market share in 2017. The increasing applications for the isolation of primary cells from blood for cell therapy research applications is estimated to drive the growth of the segment. Applications segment is divided into research applications and therapeutic applications. The research applications segment is dominating and was valued around USD 11.13 million in 2017. Growing adoption in research activities for cancer, immunology, infectious diseases, drug discovery, regenerative medicine, and cell-based therapies are contributing to the growth of the segment. End user segment is classified into blood component providers and blood centers, academic and research institutes, pharmaceutical and biotechnology companies and hospitals and transfusion centers. The blood component providers & blood centers segment is expected to grow with the highest CAGR in the forecast period. Increasing number of blood donations and rising demand for leukopaks in clinical conditions like cancer are driving the growth.

Increasing prevalence of leukemia and rise in the blood donations are boosting demand of market in forecast period. In addition, research activities including development of cell-based immunotherapies is also boosting the growth of the market. High costs of leukapheresis may restrict the growth of the market. However, innovations in R&D activities and commercialization of new products are propelling the growth of the market in forecast period.

ACCESS FULL REPORT:https://www.fiormarkets.com/report/global-leukapheresis-market-by-type-leukapheresis-devices-leukapheresis-375981.html

About the report:The globalleukapheresis market is analysed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact UsMark StonePhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Read the original post:
Global Leukapheresis Market is Expected to Reach at a CAGR of 9.60% from 2018 to 2025 - PharmiWeb.com

Global Track Etched Membrane Market : Industry Analysis and Forecast (2019-2026) by Product Type, Material, Application, End User, and Region. -…

Global Track Etched Membrane Market was valued US$ 250.00 Mn in 2018 and is expected to reach US$ XX Mn by 2026, at a XX % CAGR of around during a forecast period.

Request For View Sample Report Page :@ https://www.maximizemarketresearch.com/request-sample/16637/

Rising manufacturing of generic drugs and growing research of the developments of biological molecules, growing adoption of track-etched membrane market in various applications such as healthcare, fuel cells, telecommunication, and transportation, and rising applications in pharmaceutical and biopharmaceutical industries for research will boost the market of track-etched membrane in forecast period.

The report covers the segments in the track etched membrane market such as product type, material, application, and end-user. Based on product type, the Membrane filter segment is expected to hold the largest share of the market during the forecast period due to applicability of membrane filters in final filtration, sample preparation, filtration of aqueous and organic solutions.

By application, Cell biology is estimated to hold the largest market of the track-etched membrane during the forecast period due to rising applications in pharmaceutical and biopharmaceutical industries for research.

In terms of end-user, Pharmaceutical and biopharmaceutical industries are estimated to hold the largest share of the market in the forecast period due to the rising manufacturing of generic drugs and growing research on the developments of biological molecules.

Region-wise, North America estimated to holds the largest share of the track etched membrane market in the forecast period due to rising adoption of laboratory equipment and growing health & environmental concerns. Followed by Europe, Asia Pacific, South America, and Middle East & Africa. The track- etched membrane market in South America and Middle East & Africa is expected to expand because of an increase in health care expenditure and expansion in the health care industry during the forecast period.

Do Inquiry Before Purchasing Report Here: @ https://www.maximizemarketresearch.com/inquiry-before-buying/16637/

The objective of the report is to present a comprehensive analysis of the Global Track Etched Membrane Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Track Etched Membrane Market dynamics, structure by analyzing the market segments and project the Global Track Etched Membrane Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Track Etched Membrane Market make the report investors guide.Scope of Report Track Etched Membrane Market:

Global Track Etched Membrane Market, by Product Type

Membrane filter Capsule & cartridge filter Cell culture insertGlobal Track Etched Membrane Market, by Material

Polycarbonate PolyimideGlobal Track Etched Membrane Market, by Application

Cell biology Micrology Analytical testing OthersGlobal Track Etched Membrane Market, by End User:

Food & beverage Academic & research institute Pharmaceutical and biopharmaceutical industries OthersGlobal Track Etched Membrane Market, by Region

North America Europe Asia Pacific Middle East & Africa Latin AmericaKey Players in Global Track Etched Membrane Market

GE Healthcare Danaher Corning Merck it4ip Sterlitech Oxyphen Sarstedt BRAND GMBH Sartorius SABEU Zefon International GVS Thermo Fisher Scientific Eaton Greiner Bio-One MaCHEREY-NAGEL Avanti Lipids Polar SKC Advantec Avestin Scaffdex Merck KGaA Graver Technologies

Major Table of Contents Report

Chapter One: Track Etched Membrane Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Track Etched Membrane Market Competition, by Players

Chapter Four: Global Track Etched Membrane Market Size by Regions

Chapter Five: North America Track Etched Membrane Revenue by Countries

Chapter Six: Europe Track Etched Membrane Revenue by Countries

Chapter Seven: Asia-Pacific Track Etched Membrane Revenue by Countries

Chapter Eight: South America Track Etched Membrane Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Track Etched Membrane by Countries

Chapter Ten: Global Track Etched Membrane Market Segment by Type

Chapter Eleven: Global Track Etched Membrane Market Segment by Application

Chapter Twelve: Global Track Etched Membrane Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Track Etched Membrane Market Report at: https://www.maximizemarketresearch.com/market-report/global-track-etched-membrane-market/16637/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: Maximize Market Research Pvt. Ltd.

Email: sales@maximizemarketresearch.com

Contact: +919607065656 / +919607195908

Website: http://www.maximizemarketresearch.com

Continue reading here:
Global Track Etched Membrane Market : Industry Analysis and Forecast (2019-2026) by Product Type, Material, Application, End User, and Region. -...

Pregnancy Test for Water Delivers Fast, Easy Results on Water Safety and Quality – SciTechDaily

Tests glow green when they detect a contaminant. Credit: Northwestern University

Handheld platform technology uses single sample to test for a variety of contaminants.

A new platform technology can assess water safety and quality with just a single drop and a few minutes.

Likened to a pregnancy test, the handheld platform uses one sample to provide an easy-to-read positive or negative result. When the test detects a contaminant exceeding the EPAs standards, it glows green.

Led by researchers at Northwestern University, the tests can sense 17 different contaminants, including toxic metals such as lead and copper, pharmaceuticals, cosmetics and cleaning products. The platform which is powered by cell-free synthetic biology is so flexible that researchers can continually update it to sense more pollutants.

Professor Julius Lucks explains how to use ROSALIND. Credit: Northwestern University

Current water tests rely on a centralized laboratory that contains really expensive equipment and requires expertise to operate, said Northwesterns Julius Lucks, who led the study. Sending in a sample can cost up to $150 and take several weeks to get results. Were offering a technology that enables anyone to directly test their own water and know if they have contamination within minutes. Its so simple to use that we can put it into the hands of the people who need it most.

The research will be published today (July 6, 2020) in the journal Nature Biotechnology. Lucks is a professor of chemical and biological engineering in Northwesterns McCormick School of Engineering and a member of the Center for Synthetic Biology. Jaeyoung Jung and Khalid Alam, members of Lucks laboratory, are co-first authors of the paper.

A major challenge of ensuring water quality is that people typically cant see or taste contaminants. Northwesterns platform uses synthetic biology to sense this unnoticeable contamination, filling in the gaps where human senses fall short.

In cell-free synthetic biology, researchers take the molecular machinery including DNA, RNA and proteins out of cells, and then reprogram that machinery to perform new tasks. The idea is akin to opening the hood of the car and removing the engine, which allows researchers to use the engine for different purposes, free from the constraints of the car. In this case, Lucks team used molecular machinery from bacterial cells.

Nature has already solved this problem, Alam said. Biology has spent over three billion years evolving an elegant solution to detect contaminants.

We found out how bacteria naturally taste things in their water, Lucks added. They do so with little molecular-level taste buds. Cell-free synthetic biology allows us to take those little molecular taste buds out and put them into a test tube. We can then re-wire them up to produce a visual signal. It glows to let the user quickly and easily see if theres a contaminant in their water.

These reprogramed taste buds are freeze-dried to become shelf-stable and put into test tubes. Adding a drop of water to the tube and then flicking it sets off a chemical reaction that causes the freeze-dried pellet to glow in the presence of a contaminant.

The magic is in the tubes, Lucks said. We compose everything and freeze dry it the same process as making astronaut ice cream.

Lucks and his team call this testing platform RNA output sensors activated by ligand induction. But his team has nicknamed it ROSALIND for short, in honor of famed chemist Rosalind Franklin, who discovered the DNA double helix alongside James Watson and Francis Crick. Franklins 100th birthday would have been next month (July 25).

Her work essentially eventually enabled us to learn how to reprogram DNA to act in our technology, Lucks said.

When starting this project, Lucks took inspiration from another woman scientist in his life: his wife, Northwestern anthropologist Sera Young, who studies global food and water security and the role of household water insecurity in societal well-being.

Sera researches how poor water quality impacts peoples daily lives, Lucks said. People tend to go to the most convenient sources to get water. But if they knew that water was contaminated, they might choose to travel farther to find safer water. We want everyone to have the tools they need in order to make informed decisions.

To test the new platform in the field, Lucks, Jung, Alam and fellow Northwestern professor Jean-Francois Gaillard visited Paradise, California at the end of last year. One year earlier, a string of massive wildfires obliterated the northern California town, destroying nearly 19,000 buildings and displacing most of its population. Gaillard, a professor of environmental engineering, is an expert in the biogeochemical processes that affect metals in the aquatic system.

Wildfires basically melted the town, Lucks said. They burned down buildings and melted cars that released toxic metals into the environment.

Lucks, Gaillard and their teams tested ROSALIND alongside gold-standard water tests and discovered that ROSALIND was able to identify the presence of elevated toxic metals in the water supply. It also provided much faster and less expensive results.

Lucks and his team envision that ROSALIND could help recovery efforts like the one in Paradise, in which residents needed to perform tens of thousands of tests in order to know if their community was safe to re-enter.

Laboratory testing doesnt scale, Alam said. It shouldnt take days to get an answer to the simple question: Is my water safe to drink?'

Disasters, of course, arent the only causes of unsafe water. Heavy metals, such as copper and lead, that are naturally found in the environment can leech into pipes, contaminating household water taps and school drinking fountains. Personal care products, such as sunscreens and lotions, wash off peoples skin and end up in waterways. Unused pharmaceuticals and agricultural herbicides, too, run off into our water and end up in our sinks.

But, unless we can directly and regularly test for these pollutants, theres no way to maintain a peace of mind.

When testing water in their own home in Evanston, Illinois, Lucks and Young noted several difficulties. Consuming high levels of copper over many months or years can lead to liver damage and even death. With this concern, Lucks decided to check the copper levels in their household water. It cost $150 and took a month to receive the results.

This is a one-time test, Lucks said. It doesnt allow for checking levels from different taps in the house or temporal testing over time.

Testing for lead wasnt much easier. Lead-testing kits are available at most hardware stores. But after filling a tube with water, it still must be mailed to a centralized facility. It still costs up to $150 per test and takes weeks for results. And if people want to check their water for other contaminants, such as antibiotics, tests simply do not exist for consumers.

There has been a lot of advances in developing point-of-use diagnostics for monitoring pathogens, Jung said. But not nearly enough effort for detecting chemical contaminants.

To ensure access to safe and clean drinking water, we need technologies that will allow easy monitoring of water quality, Lucks said. With a simple, easy-to-use, handheld device like ROSALIND, you can test the water in your home or out in the field where you would want to use it most.

###

Reference: Cell-free biosensors for rapid detection of water contaminants 6 July 2020, Nature Biotechnology.DOI: 10.1038/s41587-020-0571-7

The research, Cell-free biosensors for rapid detection of water contaminants, was supported by the National Science Foundation (award numbers 1452441 and 1929912), the National Institutes of Health (award number R35 GM118157), the Crown Family Center for Jewish and Israel Studies at Northwestern University and Searle Funds at The Chicago Community Trust.

Editors note: Northwestern startup company, Stemloop, has optioned the ROSALIND technology with plans to commercialize it. Lucks, Alam and Northwestern will have financial interests (royalties, equities), if it is commercialized.

See original here:
Pregnancy Test for Water Delivers Fast, Easy Results on Water Safety and Quality - SciTechDaily